Medicine Recommendations

Rheumatoid arthritis (LSCMMG pathway)

Juvenile Idiopathic Arthritis (JIA) in Adult Patients  

Treating moderate to severe atopic dermatitis - NICE TA814

NICE TA814 - Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis

MHRA Drug Safety Update, 26 April 2023

JAK Inhibitors MHRA Drug Safety Update

Treatment of house dust mite sensitisation

Oral Retinoid for Psoriasis

MHRA Drug Safety Update - Oral retinoids: pregnancy prevention—reminder of measures to minimise teratogenic risk

COPD

COPD

Treatment of pain in knee osteoarthritis and plantar fasciitis

Rheumatoid arthritis (LSCMMG pathway)

Crohn's disease, 1st line biologic (NICE TA187) and LSCMMG Recommendation

NICE TA187 - Infliximab and adalimumab for the treatment of Crohn's Disease

First line biologic for moderate to severe active ulcerative colitis after the failure of conventional therapy (NICE TA329) and LSCMMG Recommendation

NICE TA329  Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262)

Crohn's disease, 2nd line biologic (NICE TA187) and LSCMMG Recommendation

NICE TA187 - Infliximab and adalimumab for the treatment of Crohn's Disease

Second line in Psoriatic Arthritis (PsA) following discontinuation of first anti-TNF due to an adverse event or primary or secondary inefficacy

Second line biologic for moderate to severe active ulcerative colitis after the failure of conventional therapy (NICE TA329) and LSCMMG Recommendation

NICE TA329 - Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy

Ankylosing spondylitis (NICE TA383)

NICE TA383 - TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis

Juvenile Idiopathic Arthritis (JIA) in Adult Patients

Non-radiographic axial spondyloarthritis (NICE TA383)

NICE TA383 - TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis

Prevention of recurrence of ulcerative colitis following surgery

Psoriatic arthritis (NICE TA199)

NICE TA199 - Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis

Severe Plaque Psoriasis (NICE TA146)

NICE TA146 - Adalimumab for the treatment of adults with psoriasis